•
Phase III randomized, placebo-controlled, double-blind, multicenter
•
Olaparib tablets administered at 600 mg daily for up to 2 years.
PAOLA 1
•
Stratification factors:
•
First-line treatment outcome (complete resection after initial surgery and NED at screening,
•
Complete resection at interval debulking surgery and NED at screening,
•
Incomplete resection at initial or interval debulking surgery and in CR at screening,
•
PR at screening)
•
gBRCA status (yes, no, unknown)
